CLINICAL_TRIALS trial_result · 2019-01-16

Clinical Trial Update: A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL) [Phase 2]

Phase 2 trial evaluating rituximab (MabThera) as first-line treatment for chronic lymphocytic leukemia (CLL) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Hoffmann-La Roche | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Status: COMPLETED | Results posted: 2019-01-16